Wall Street analyst estimates for Genprex, Inc. (GNPX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-12-02 | $-6160.00 | ||
| 2026-08-14 | $-9.40 | ||
| 2026-05-13 | $-14.07 | ||
| 2026-03-30 | $-25.30 | $-286.00 | +91.2% |
| 2025-11-14 | $-109.89 | $-275.00 | +60.0% |
| 2025-08-08 | $-187.00 | $-15.62 | -1097.2% |
| 2025-05-12 | $-285.71 | $-55.88 | -411.3% |
| 2025-04-01 | $-462.00 | $-18.04 | -2461.0% |
Valuation Ratios
| Price / Book | 0.10 |
| EV / EBITDA | 0.85 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | $5885 | $13070 | $22777 | $22534 | $25575 | $15004 | $6693 | 0 |
| Gross Profit | 0 | 0 | -$5885 | -$13070 | -$22777 | -$22534 | -$25575 | -$15004 | -$6693 | 0 |
| Research & Development | $354883 | $289934 | $971427 | $2.0M | $7.3M | $9.0M | $11.5M | $17.6M | $10.5M | $9.4M |
| Selling, General & Admin | $3.8M | $3.0M | $11.4M | $8.7M | $10.6M | $11.7M | $12.3M | $13.4M | $10.6M | $6.1M |
| Operating Expenses | $4.1M | $3.3M | $12.4M | $10.7M | $17.9M | $20.6M | $23.8M | $31.1M | $21.2M | $15.5M |
| Operating Income | -$4.1M | -$3.3M | -$12.4M | -$10.7M | -$18.0M | -$20.7M | -$23.8M | -$31.1M | -$21.2M | -$15.5M |
| EBITDA | -$4.1M | -$3.3M | -$12.3M | -$10.6M | -$17.9M | -$20.6M | -$23.7M | -$30.8M | -$21.1M | -$15.5M |
| Interest Expense | 0 | $1890 | $37982 | 0 | 0 | 0 | 0 | 0 | 0 | $739935 |
| Pre-tax Income | -$4.1M | -$3.3M | -$12.4M | -$10.7M | -$17.9M | -$20.7M | -$23.7M | -$30.9M | -$21.1M | -$16.2M |
| Income Tax | 0 | $80 | $29184 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$4.1M | -$3.3M | -$12.4M | -$10.7M | -$17.9M | -$20.7M | -$23.7M | -$30.9M | -$21.1M | -$16.2M |
| EPS | $-16830.00 | $-12705.00 | $-39567.00 | $-29304.00 | $-22198.00 | $-19305.00 | $-21780.00 | $-24838.00 | $-5872.98 | $-382.80 |
| EPS (Diluted) | $-16786.00 | $-12683.00 | $-39534.00 | $-29249.00 | $-22198.00 | $-19305.00 | $-21780.00 | $-24816.00 | $-5872.98 | $-382.80 |
| Shares Outstanding (Diluted) | $246 | $261 | $313 | $364 | $807 | $1070 | $1090 | $1243 | $3642 | $42397 |
Price
| Price | $3.41 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BDRX · BIVI · CERO · CMMB · CNSP · GRI · INM
Explore sector: Healthcare · Biotechnology
More sections of GNPX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks